Form 4: Halozyme CEO Helen Torley Executes Pre-Planned Stock Option Exercises and Sales

Halozyme Therapeutics' President and CEO, Helen Torley, reported the exercise of stock options and subsequent sale of common shares totaling approximately $3.39 million over three days in July 2025, all conducted under a pre-established Rule 10b5-1 trading plan.

Summary

• Helen Torley, President and CEO, and a Director of Halozyme Therapeutics, Inc. (HALO), reported a series of transactions involving the company's common stock.
• The transactions, occurring on July 8, 9, and 10, 2025, were executed pursuant to a Rule 10b5-1 written trading plan adopted on March 21, 2025.
• On each of these three days, Ms. Torley exercised options to acquire 20,000 shares of common stock at an exercise price of $8.11 per share, totaling 60,000 shares acquired.
• Concurrently with each exercise, Ms. Torley disposed of the same number of shares (20,000 per day, totaling 60,000 shares) at weighted average sales prices ranging from $54.483 to $57.617 per share.
• The total proceeds from the sale of these 60,000 shares amounted to approximately $3,387,602.94.
• The options exercised were part of a grant from February 3, 2016, with a ten-year term expiring in February 2026.
• Following these transactions, Ms. Torley's direct beneficial ownership of common stock remained at 733,719 shares, while her direct beneficial ownership of derivative securities (options) decreased from 316,569 to 256,569.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This is a routine, pre-planned insider transaction (exercise and sell) under a 10b5-1 plan, which is a common practice for executives managing their compensation and liquidity. It does not indicate a change in company outlook or performance.

Positives

• The transactions were conducted under a pre-established Rule 10b5-1 trading plan, indicating a structured and transparent approach to insider stock sales.
• The exercise of options at a significantly lower price ($8.11) compared to the sale price (ranging from $54.483 to $57.617) demonstrates the value appreciation of the stock and the profitability of the options.

Negatives

• The sale of shares by a key executive, even if pre-planned, reduces their direct equity stake in the company, which some investors might interpret as a slight reduction in alignment of interests.

Future Outlook

This Form 4 filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports past insider transactions.

Industry Context

This filing is a routine insider transaction report specific to Halozyme Therapeutics and does not provide broader industry trends or competitive insights. It reflects an executive's pre-planned management of their equity compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale represents a routine liquidity event for an executive and does not necessarily signal a change in company fundamentals. The pre-planned nature under Rule 10b5-1 provides transparency.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

Halozyme Therapeutics, HALO, SEC Form 4, Insider Trading, Stock Options, Rule 10b5-1, Executive Compensation, Share Sale, Biotechnology, Pharmaceuticals